Dr. Judith A. Salerno
CCF and ASCO have benefited greatly from a long-term relationship with Susan G. Komen. Komen’s generous support over the years has resulted in programs that address quality, access, and delivery of care for patients with breast cancer; breast cancer research; and dissemination of knowledge and training for clinicians and researchers at Breast Cancer Symposia.
Komen’s earlier $1 million grant, received in 2013, supported the development of a CancerLinQ breast cancer prototype, which enabled ASCO to establish the proof of concept needed to create a rapid learning system across all forms of cancer. The organization’s second grant will support system components and professional expertise, such as breast cancer clinical decision support, a patient portal customized for patients with breast cancer, and the incorporation of breast cancer–specific guidelines and measures into the health platform.
“The Conquer Cancer Foundation gratefully acknowledges and sincerely appreciates Komen’s continued support of CancerLinQ, which has the potential to benefit every patient with cancer, including [those with] breast cancer,” said Nancy R. Daly, MS, MPH, executive vice president and chief philanthropic officer of CCF.
When CCF and ASCO first approached Komen about CancerLinQ in 2010, “big data” was not as prominent as it is today. Yet, the idea of a rapid learning system like CancerLinQ, in which doctors, patients, and researchers can learn from each patient’s cancer experience, piqued Komen’s interest.
“Collaboration with CCF, ASCO, and others is critical to making quick and meaningful progress against breast cancer,” Dr. Salerno continued. “We know that no single organization will end breast cancer; each organization brings a unique set of perspectives and expertise. By working together, we can more quickly realize our vision of a world without breast cancer.”
Komen remains involved in the progress of CancerLinQ through its participation on the CancerLinQ Patient Advisory Committee and Data Governance Oversight Committee.
“Komen has long believed in keeping the patient at the center of cancer innovation,” Dr. Salerno said. “We’ve been a leader in making sure the patient perspective is included in our peer-review and decision-making processes. Projects like CancerLinQ need the patient voice to help inform the design and use of the system, and we are so glad that we are able to help provide that voice.”
Komen’s key mission priorities include a focus on metastatic and aggressive forms of breast cancer, supporting the next generation of breast cancer researchers, and ensuring health equity for everyone. ASCO members can become involved in Komen programs, both at the local and national level, by checking to see if there is a Komen affiliate in their area and by following Komen on Facebook, Twitter, Instagram, and Pinterest.